DMC, Recombinant, Human (Dendritic cell and Monocyte Chemokine-like Protein, VEGF Co-regulated Chemokine 1, VCC1) (BSA Free)

Molecular Biology / MB-Growth Factors

-20°C

Supplied as a lyophilized powder in PBS.

Dendritic cell and monocyte chemokine-like protein (DMC), also known as VEGF-correlated chemokine-1 (VCC-1), is a secreted molecule with a size and predicted three-dimensional folding pattern similar to that of chemokines CXCL8/IL-8 and CXCL14/BRAK (1, 2). It has no predicted N-glycosylation site. Cleavage of a 23 amino acid (aa) signal sequence yields the mature 96 aa human DMC. DMC is constitutively produced by airway and intestinal epithelium (1). It induces the chemotaxis of quiescent, but not LPS-activated peripheral blood monocytes and dendritic cells (1). DMC expression is increased in endothelial cells when they are induced to form tubes in vitro (2). Transgenic overexpression in NIH3T3 cells causes upregulation of proteins such as VEGF and FGF basic, and increases cell growth rate and tumorigenicity (2). DMC, plus two other chemokines that play roles in angiogenesis, CXCL1/GRO and CXCL8/IL-8, show a correlated expression pattern with VEGF in primary lung, breast and esophageal tumors (2). DMC is, therefore, suggested to play a role in tumor angiogenesis. Mature human DMC shares 73%, 71% and 64% amino acid sequence identity with bovine, mouse and rat DMC, respectively.

Source:
A DNA sequence encoding the mature human DMC (Leu 24-Leu 119; Accession # NP_940879) was expressed in E. coli.

Molecular Mass:
The 96 amino acid residue recombinant human DMC has a predicted molecular mass of approximately 11.3kD.

Endotoxin Level:
< 1.0 EU per 1 μg of the protein as determined by the LAL method.

Activity:
Measured by its ability to induce VEGF expression in endothelial cells (Weinstein, E.J. et al., 2006, BBRC, 350:74). The ED50 for this effect is typically 1-5ug/ml.

Recontitution:
It is recommended that sterile PBS be added to the vial to prepare a working stock solution of no less than 100ug/ml. The carrier-free protein should be used immediately upon reconstitution to avoid losses in activity due to non-specific binding to the inside surface of the vial. For long term storage as a dilute solution, a carrier protein (e.g. 0.1% HSA or BSA) should be added to the vial.

Storage and Stability:
Lyophilized samples are stable for up to twelve months at -20°C. Upon reconstitution, this protein can be stored under sterile conditions at 2-8°C for one month or at -20°C in a manual defrost freezer for three months without detectable loss of activity. Avoid repeated freeze-thaw cycles.